Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Hurst

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)|May 1, 1997
Eye drop container delivery: a source of response variation?E J German, M A Hurst, D Wood
Eye (London, England)|January 1, 1990
Comparing clinical tests of visual function in cataract with the patient's perceived visual disabilityD B Elliott, M A Hurst, J Weatherill
Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)|August 6, 1998
A novel system for the objective classification of iris colour and its correlation with response to 1% tropicamideE J German, M A Hurst, D Wood, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2000
IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositisD A Mosca, M A Hurst, W So, et al.
Ophthalmic Epidemiology|June 1, 1995
Validation of methods for the assessment of cataract progression in the Roche European-American Anticataract Trial (REACT)L T Chylack, J K Wolfe, J Friend, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1997
Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activityD A Steinberg, M A Hurst, C A Fujii, et al.
Biopolymers|August 10, 2000
Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analoguesJ Chen, T J Falla, H Liu, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)|May 1, 1997
Eye drop container delivery: a source of response variation?E J German, M A Hurst, D Wood
Eye (London, England)|January 1, 1990
Comparing clinical tests of visual function in cataract with the patient's perceived visual disabilityD B Elliott, M A Hurst, J Weatherill
Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)|August 6, 1998
A novel system for the objective classification of iris colour and its correlation with response to 1% tropicamideE J German, M A Hurst, D Wood, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2000
IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositisD A Mosca, M A Hurst, W So, et al.
Ophthalmic Epidemiology|June 1, 1995
Validation of methods for the assessment of cataract progression in the Roche European-American Anticataract Trial (REACT)L T Chylack, J K Wolfe, J Friend, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1997
Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activityD A Steinberg, M A Hurst, C A Fujii, et al.
Biopolymers|August 10, 2000
Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analoguesJ Chen, T J Falla, H Liu, et al.
Pageof 2